Fumarate hydratase-deficient renal cell carcinoma (FH-RCC) is a rare and aggressive tumor affecting mostly younger patients. This is the first study to assess the expression of programmed death-1 (PD-1) receptor/PD-1 ligand (PD-L1) in FH-RCC. Formalin-fixed paraffin-embedded samples from 13 FH-RCCs collected in an international multi-institutional study, were evaluated by immunohistochemistry (IHC) for PD-1/PD-L1 reactivity in tumor cells and tumor infiltrating lymphocytes (TILs). PD-1/PD-L1 expression was further evaluated by qPCR. By IHC, PD-1 was negative in tumor cells in all 13 cases. PD-L1 was positive in tumor cells in 2/13 cases, weak positive in 7/13, and negative in 4/13 cases, respectively. In TILs, PD-1 was positive in 1/13, weak positive in 3/13, and negative in 9/13 cases. In TILs, PD-L1 was weak positive by IHC in 5/13, and negative in 8/13 cases, respectively. qPCR confirmed the result for 2 of 3 IHC weak positive PD-1 samples. Of 7 IHC weak positive samples (in tumor cells), PD-L1 mRNA was detected in all 7 tumors. The majority of FH-RCCs did not express PD-1/PD-L1 by IHC, which was confirmed by molecular analysis. PD-1/PD-L1 expression in FH-RCC is restricted to a proportion of cases which may benefit from targeted therapies.

Bart's Cancer Center London United Kingdom

Calgary Laboratory Services University of Calgary Calgary AB Canada

Department of Pathology Bellvitge Biomedical Research Institute Barcelona Spain

Department of Pathology Charles University Medical Faculty and Charles University Hospital Plzen Czech Republic

Department of Pathology Faculty of Medicine University of British Columbia Royal Columbian Hospital Vancouver BC Canada

Department of Pathology Instituto Nacional de Cancerologia Mexico City Mexico

Department of Pathology Medical College Wisconsin Milwaukee WI USA

Department of Pathology University Erlangen Germany

Department of Urology Charles University Medical Faculty and Charles University Hospital Plzen Czech Republic

Hospital Cochin Paris France

Robert J Tomsich Pathology and Laboratory Medicine Institute Cleveland Clinic Cleveland OH USA

000      

00000naa a2200000 a 4500

001      

bmc18024736

003      

CZ-PrNML

005      

20180712090253.0

007      

ta

008      

180709s2017 xxu f 000 0|eng||

009      

AR

024    7_

$a 10.1016/j.anndiagpath.2017.04.007 $2 doi

035    __

$a (PubMed)28807336

040    __

$a ABA008 $b cze $d ABA008 $e AACR2

041    0_

$a eng

044    __

$a xxu

100    1_

$a Alaghehbandan, Reza $u Department of Pathology, Faculty of Medicine, University of British Columbia, Royal Columbian Hospital, Vancouver, BC, Canada.

245    10

$a Programmed death-1 (PD-1) receptor/PD-1 ligand (PD-L1) expression in fumarate hydratase-deficient renal cell carcinoma / $c R. Alaghehbandan, J. Stehlik, K. Trpkov, C. Magi-Galluzzi, E. Condom Mundo, M. Pane Foix, D. Berney, M. Sibony, S. Suster, A. Agaimy, DP. Montiel, K. Pivovarcikova, K. Michalova, O. Daum, O. Ondic, P. Rotterova, M. Dusek, M. Hora, M. Michal, O. Hes,

520    9_

$a Fumarate hydratase-deficient renal cell carcinoma (FH-RCC) is a rare and aggressive tumor affecting mostly younger patients. This is the first study to assess the expression of programmed death-1 (PD-1) receptor/PD-1 ligand (PD-L1) in FH-RCC. Formalin-fixed paraffin-embedded samples from 13 FH-RCCs collected in an international multi-institutional study, were evaluated by immunohistochemistry (IHC) for PD-1/PD-L1 reactivity in tumor cells and tumor infiltrating lymphocytes (TILs). PD-1/PD-L1 expression was further evaluated by qPCR. By IHC, PD-1 was negative in tumor cells in all 13 cases. PD-L1 was positive in tumor cells in 2/13 cases, weak positive in 7/13, and negative in 4/13 cases, respectively. In TILs, PD-1 was positive in 1/13, weak positive in 3/13, and negative in 9/13 cases. In TILs, PD-L1 was weak positive by IHC in 5/13, and negative in 8/13 cases, respectively. qPCR confirmed the result for 2 of 3 IHC weak positive PD-1 samples. Of 7 IHC weak positive samples (in tumor cells), PD-L1 mRNA was detected in all 7 tumors. The majority of FH-RCCs did not express PD-1/PD-L1 by IHC, which was confirmed by molecular analysis. PD-1/PD-L1 expression in FH-RCC is restricted to a proportion of cases which may benefit from targeted therapies.

650    _2

$a dospělí $7 D000328

650    _2

$a antigeny CD274 $x metabolismus $7 D060890

650    _2

$a karcinom z renálních buněk $x metabolismus $x patologie $7 D002292

650    _2

$a přežití po terapii bez příznaků nemoci $7 D018572

650    _2

$a ženské pohlaví $7 D005260

650    _2

$a fumarasa $x nedostatek $x metabolismus $7 D005649

650    _2

$a lidé $7 D006801

650    _2

$a imunohistochemie $x metody $7 D007150

650    _2

$a nádory ledvin $x metabolismus $x patologie $7 D007680

650    _2

$a tumor infiltrující lymfocyty $x metabolismus $x patologie $7 D016246

650    _2

$a mužské pohlaví $7 D008297

650    _2

$a lidé středního věku $7 D008875

650    _2

$a antigeny CD279 $x metabolismus $7 D061026

655    _2

$a časopisecké články $7 D016428

700    1_

$a Stehlik, Jan $u Department of Pathology, Charles University, Medical Faculty and Charles University Hospital Plzen, Czech Republic.

700    1_

$a Trpkov, Kiril $u Calgary Laboratory Services, University of Calgary, Calgary, AB, Canada.

700    1_

$a Magi-Galluzzi, Cristina $u Robert J. Tomsich Pathology and Laboratory Medicine Institute, Cleveland Clinic, Cleveland, OH, USA.

700    1_

$a Condom Mundo, Enric $u Department of Pathology, Bellvitge Biomedical Research Institute (IDIBELL), Barcelona, Spain.

700    1_

$a Pane Foix, Maria $u Department of Pathology, Bellvitge Biomedical Research Institute (IDIBELL), Barcelona, Spain.

700    1_

$a Berney, Daniel $u Bart's Cancer Center, London, United Kingdom.

700    1_

$a Sibony, Mathilde $u Hospital Cochin, Paris, France.

700    1_

$a Suster, Saul $u Department of Pathology, Medical College Wisconsin, Milwaukee, WI, USA.

700    1_

$a Agaimy, Abbas $u Department of Pathology, University Erlangen, Germany.

700    1_

$a Montiel, Delia Perez $u Department of Pathology, Instituto Nacional de Cancerologia, Mexico City, Mexico.

700    1_

$a Pivovarcikova, Kristyna $u Department of Pathology, Charles University, Medical Faculty and Charles University Hospital Plzen, Czech Republic.

700    1_

$a Michalova, Kvetoslava $u Department of Pathology, Charles University, Medical Faculty and Charles University Hospital Plzen, Czech Republic.

700    1_

$a Daum, Ondrej $u Department of Pathology, Charles University, Medical Faculty and Charles University Hospital Plzen, Czech Republic.

700    1_

$a Ondic, Ondrej $u Department of Pathology, Charles University, Medical Faculty and Charles University Hospital Plzen, Czech Republic.

700    1_

$a Rotterova, Pavla $u Department of Pathology, Charles University, Medical Faculty and Charles University Hospital Plzen, Czech Republic.

700    1_

$a Dusek, Martin $u Department of Pathology, Charles University, Medical Faculty and Charles University Hospital Plzen, Czech Republic.

700    1_

$a Hora, Milan $u Department of Urology, Charles University, Medical Faculty and Charles University Hospital Plzen, Czech Republic.

700    1_

$a Michal, Michal $u Department of Pathology, Charles University, Medical Faculty and Charles University Hospital Plzen, Czech Republic.

700    1_

$a Hes, Ondrej $u Department of Pathology, Charles University, Medical Faculty and Charles University Hospital Plzen, Czech Republic. Electronic address: hes@medima.cz.

773    0_

$w MED00166541 $t Annals of diagnostic pathology $x 1532-8198 $g Roč. 29, č. - (2017), s. 17-22

856    41

$u https://pubmed.ncbi.nlm.nih.gov/28807336 $y Pubmed

910    __

$a ABA008 $b sig $c sign $y a $z 0

990    __

$a 20180709 $b ABA008

991    __

$a 20180712090545 $b ABA008

999    __

$a ok $b bmc $g 1316867 $s 1021657

BAS    __

$a 3

BAS    __

$a PreBMC

BMC    __

$a 2017 $b 29 $c - $d 17-22 $e 20170424 $i 1532-8198 $m Annals of diagnostic pathology $n Ann. diagn. pathol. $x MED00166541

LZP    __

$a Pubmed-20180709